The deal – financial terms of which were not disclosed – will see Stemcell use BioLife’s CryoStor cGMP media in 50 new products – ranging from bone marrow, peripheral blood, umbilical cord blood, and umbilical cord tissue – it plans to market to the research community.
The firms have worked together since 2009 when Stemcell started distributing BioLife’s range of biopreservation media to customers in academia and biopharmaceutical research and development (R&D).
This was acknowledged by David Llewellyn, director of business operations at Stemcell, who said: “BioLife has become an increasingly strategic supplier of our research products. Our customers value the quality and performance of BioLife’s biopreservation media products.
“Along with our own internal research, customer feedback gives us confidence to incorporate CryoStor into our new primary cell product portfolio.”